Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 27, 2009
- Patients, Doctors Remain Calm Despite EASD Reports on Lantus: sanofi-aventis
July 27, 2009
- Cravit No. 1 on HP Market, No. 2 on GP Market: Rep Track Survey
July 27, 2009
- Merck Serono Aims at Becoming No. 1 in Reproductive Health, Metabolic Oncology
July 27, 2009
- Hisamitsu to Acquire Noven Pharm. to Strengthen US Business Platform
July 27, 2009
- Immunology/Inflammation MTPC's 3rd Top-Priority Field
July 27, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 27, 2009
- Nat'l Univ. Hospitals Apprehensive of Negative Effects of Use of Generics on Their Research
July 27, 2009
- R&D NEWS IN BRIEF
July 27, 2009
- Zeria Launches Additional OTC Versions of Acinon
July 27, 2009
- Korosho to Build Up Network of Global Clinical Research Centers
July 27, 2009
- R&D NEWS IN BRIEF
July 20, 2009
- Japan Biotechnology Conference Kicked Off by 20 Biotech Firms
July 20, 2009
- ASCO 2009 Highlight Seminar by the Matson Jack Group
July 20, 2009
- Pfizer Discontinues PIII Trial of Sutent in Metastatic CRC
July 20, 2009
- GENERICS NEWS IN BRIEF
July 20, 2009
- Survey on Generics of Anticancer Drugs Shows Gaps between Generic Firms and Healthcare Professionals
July 20, 2009
- Anplag to Be Major Target for Generic NHI Price Listing in November
July 20, 2009
- REGULATORY NEWS IN BRIEF
July 20, 2009
- Pfizer Offers Reduced Working-Hour Program for MRs
July 20, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…